John R. Warren
@Farallon Capital Management Llc
Latest period2024 - Q3ReportedManaged Assets$20.437BTotal holdings153
Assets growth rate-3.56%Assets growth rate (2-Q avg)-3.73%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Farallon Capital Management Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 153 positions.
Assets under management
The assets under management (AUM) of Farallon Capital Management Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 20.437B in assets, with a quarterly growth rate of -3.56% and a 2-quarter average growth rate of -3.73%. The portfolio is managed by John R. Warren, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
AZNAstrazeneca Plc
| 0% | $187.934M 2.41M shares@ $78.0 avg price | Exited |
4626⤦Iqiyi Inc
| 0% | $162.081M 163.1M shares@ $1.0 avg price | Exited |
CERECerevel Therapeutics Hldng I
| 0% | $48.659M 1.19M shares@ $40.89 avg price | Exited |
CRSPCrispr Therapeutics Ag
| 0% | $28.625M 530,000 shares@ $54.01 avg price | Exited |
SYRESpyre Therapeutics Inc
| 0% | $15.658M 666,000 shares@ $23.51 avg price | Exited |
PCGPg&e Corp
| 0% | $12.088M 692,323 shares@ $17.47 avg price | Exited |
RIORio Tinto Plc
| 0% | $9.065M 137,500 shares@ $65.93 avg price | Exited |
BACABerenson Acquisition Corp I
| 0% | $3.043M 285,715 shares@ $10.66 avg price | Exited |
ARYDArya Sciences Acqu Corp Iv
| 0% | $2.292M 200,000 shares@ $11.46 avg price | Exited |
NRIXNurix Therapeutics Inc
| 0% | $2.271M 108,799 shares@ $20.87 avg price | Exited |